Dr. Michael Rheinnecker is Co-Founder and CEO of Sequantrix^TM. He is a biotech entrepreneur with over 30 years of experience in research, licensing and management. He was also Managing Partner at TechnoStart Ventures and founding investor of Graffinity (exit as Santhera, SWX:SANN) and Complex Biosystems (exit as Ascendis Pharma, NASDAQ:ASND). Michael received his Ph.D. in molecular biology from Cambridge University in the laboratory of Sir Alan R. Fersht FRS at the MRC Unit for Protein Function and Design.